Alessandro Testori
European Organisation for Research and Treatment of Cancer · 353 works · 33,742 citations · h-index 72
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
- Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience
- The role of BRAF V600 mutation in melanoma
- Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
- Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
- Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
- Mitf regulation of Dia1 controls melanoma proliferation and invasiveness